Scholarlink

<p><i>Limosilactobacillus reuteri</i> DSM 17938 (<i>L. reuteri</i> DSM 17938) was one of the most widely used probiotics in humans for gastrointestinal disorders, but few studies have investigated its role in drug-induced liver injury (DILI). Here, we evaluated the efficacy of <i>L. reuteri</i> DSM 17938 using a mouse model of DILI induced by triptolide. Pregavage of <i>L. reuteri</i> DSM 17938 for 1 week remarkably lowered hepatic inflammatory cytokines level and oxidative stress, with diminished serum alanine transaminase and aspartate aminotransferase levels. Metabolomics and RT-qPCR analysis confirmed its ability in ameliorating TP-disrupted hepatic fatty acid β oxidation. Genome annotation of <i>L. reuteri</i> showed its ability to modulate energy metabolism. Targeted metabolomics demonstrated that <i>L. reuteri</i> DSM 17938 modified the short fatty acid profiles in cecum, especially enhancing propionate levels. Further experiments found that <i>L. reuteri</i> DSM 17938 can activate AMPK signaling by upregulating gut microbiota–derived propionate level, thus restoring impaired mitochondrial biogenesis and energy supply processes to recover energy homeostasis, which leads to diminished ROS production and oxidative stress injury in hepatocytes. Besides, AMPK inhibitor dorsomorphin abolished all the effects on propionate protecting mitochondria and energy metabolism. This study established probiotic therapy of <i>L. reuteri</i> DSM 17938 as a preventive intervention for DILI in clinical. We also revealed that <i>L. reuteri</i> DSM 17938 can activate AMPK signaling by propionate, facilitating a deeper understanding of the action mechanism of <i>L. reuteri</i> DSM 17938 against acute liver injury and contributing to the development of its postbiotics and wider applications.</p> Graphical Abstract <p>Mechanism illustration of <i>Limosilactobacillus reuteri </i>DSM 17938 alleviating TP-induced liver injury by enhancing AMPK signaling pathway via propionate (Created with Biorender. com).</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Probiotic Limosilactobacillus reuteri DSM 17938 Alleviates Acute Liver Injury by Activating the AMPK Signaling via Gut Microbiota–Derived Propionate

  • 期刊论文

  • 发表日期：

    2025年1月28日

查看全文
  • Yuting Zhao,
  • Weiqi Xie,
  • Jingyi Duan,
  • Fei Li

摘要

Limosilactobacillus reuteri DSM 17938 (L. reuteri DSM 17938) was one of the most widely used probiotics in humans for gastrointestinal disorders, but few studies have investigated its role in drug-induced liver injury (DILI). Here, we evaluated the efficacy of L. reuteri DSM 17938 using a mouse model of DILI induced by triptolide. Pregavage of L. reuteri DSM 17938 for 1 week remarkably lowered hepatic inflammatory cytokines level and oxidative stress, with diminished serum alanine transaminase and aspartate aminotransferase levels. Metabolomics and RT-qPCR analysis confirmed its ability in ameliorating TP-disrupted hepatic fatty acid β oxidation. Genome annotation of L. reuteri showed its ability to modulate energy metabolism. Targeted metabolomics demonstrated that L. reuteri DSM 17938 modified the short fatty acid profiles in cecum, especially enhancing propionate levels. Further experiments found that L. reuteri DSM 17938 can activate AMPK signaling by upregulating gut microbiota–derived propionate level, thus restoring impaired mitochondrial biogenesis and energy supply processes to recover energy homeostasis, which leads to diminished ROS production and oxidative stress injury in hepatocytes. Besides, AMPK inhibitor dorsomorphin abolished all the effects on propionate protecting mitochondria and energy metabolism. This study established probiotic therapy of L. reuteri DSM 17938 as a preventive intervention for DILI in clinical. We also revealed that L. reuteri DSM 17938 can activate AMPK signaling by propionate, facilitating a deeper understanding of the action mechanism of L. reuteri DSM 17938 against acute liver injury and contributing to the development of its postbiotics and wider applications.

Graphical Abstract

Mechanism illustration of Limosilactobacillus reuteri DSM 17938 alleviating TP-induced liver injury by enhancing AMPK signaling pathway via propionate (Created with Biorender. com).